Patent intelligence · US
US 12084350
Allotrope of carbon having increased electron delocalization
Allotrope of carbon having increased electron delocalization
Patent details — US 12084350
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 10, 2024
- Expiration
- Sep 5, 2044
- Applicant
- Structured Nano Carbon LLC
- Claims
- 17
- CPC classes
- A61K, A61K33/44
Quick answer
US 12084350 (Allotrope of carbon having increased electron delocalization) is held by Structured Nano Carbon LLC. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Structured Nano Carbon LLC
- Grant date
- Expiration
- Claims
- 17
- CPC classes
- A61K, A61K33/44
More from Structured Nano Carbon LLC
Related pharmaceutical patents in our USPTO index.
-
US 12279630
Treatment and prevention of seed allergies
granted -
US 12251417
Antimicrobial compounds from the genus Delftia
granted -
US 12139522
T-cells comprising two different chimeric antigen receptors and uses thereof
granted -
US 12134650
Compositions targeting GABRA2 and methods for diagnosis and treatment of cancer
granted -
US 12023348
EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
granted -
US 11944644
T-cells comprising anti-CD38 and anti-CD138 chimeric antigen receptors and uses thereof
granted -
US 11932871
Methods of culturing t cells and uses of same
granted
Frequently asked questions
What is US patent 12084350?
US 12084350 (Allotrope of carbon having increased electron delocalization) is held by Structured Nano Carbon LLC. Status: granted. Granted Sep 10, 2024. Expires Sep 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12084350?
Structured Nano Carbon LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 93 pharmaceutical patents for this assignee.
When does US 12084350 expire?
Our index shows an expiration date of Sep 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.